We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Nvidia (NVDA) and Tesla (TSLA) Are Aggressive Growth Stocks
This week Brian has a little something different in store, a growth stock that doesn’t have a strong Growth Style Score. The first stock Brian looks at is Nvidia (NVDA - Free Report) and preview reviews this Zacks Rank #1 (Strong Buy) and looks at the earnings estimate revisions. The earnings history is rather strong, and Brian points out on the chart that dip buyers have consistently been rewarded. The next stock is the thing that is different about this video. Normally Brian Bolan selects stocks with a solid Growth Style Score, but Tesla (TSLA - Free Report) has an F. Brian explains that as the quarter comes to an end there is a high probability that the company is producing 5K Model 3 cars a week. This is the growth that he is concerned about and points to a recent article he published on the topic. Sales numbers are due out on July 6, and Brian suggests that the Goldman Sach estimate of 22K could be eclipsed by the number of Model 3 sales alone! Brian Bolan discloses that he owns TSLA in his trading and retirement accounts.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>